OR WAIT 15 SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2020 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Millipore Strengthens Bioprocess Division with Serologicals Acquistion
Pharmaceutical Technology Editors
Millipore Corporation (Billerica, MA, www.millipore.com) and Serologicals Corporation (Norcross, GA, www.serologicals.com) have announced an agreement in which Millipore will acquire Serologicals in a cash transaction valued at approximately $1.4 billion and set to close by June 30, 2006.
Millipore Corporation (Billerica, MA, www.millipore.com) and Serologicals Corporation (Norcross, GA, www.serologicals.com) have announced an agreement in which Millipore will acquire Serologicals in a cash transaction valued at approximately $1.4 billion. The deal is set to close by June 30, 2006.
The agreement strengthens Millipore’s workforce to 5800 employees and builds its projected combined annual revenue to $1.4 billion.
Serologicals provides biological products, technologies, and services and maintains operations in both bioprocessing and research. The acquisition will boost Millipore’s Bioprocess Division in various growth segments, including drug discovery, antibodies, cell biology reagents, and stem cell research. The company also gains a cell-culture supplements offering, thereby facilitating entry into the $1-billion upstream bioprocessing market. The move reportedly makes Millipore the only company in the life sciences industry with both upstream cell-culture and downstream separation offerings for biopharmaceutical production.
Related Content:
PharmTech News